TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph
Brief Summary: This study is a multicenter trial of treatment for young ALL patients. All ALL patients will receive the same steroid pre-phase in order to evaluate sensitivity or resistance. Then, patients will be included into 3 specific trials according to biological features (immunophenotype, cytogenetics, and molecular biology).

Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2005:

* T ALL or B ALL non Ph (N=810 patients planned).
* GRAALL 2005 R: B ALL non Ph CD20+ (N=220 patients planned).
* GRAAPH 2005: ALL Ph+ (N=270 patients planned)


Options:
A: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Imatinib Mesylate; Assigned to Arm(s): N/A
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
D: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD
Brief Summary: The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.


Options:
A: Arm Label: ABT-335 plus rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 plus rosuvastatin | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: ABT-335 plus rosuvastatin; Assigned to Arm(s): ABT-335 plus rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Double Dummy, Randomised, Multicentre Study to Compare the Efficacy and Safety of Fulvestrant 250mg With Arimidex 1mg as a Secondary-line Therapy in the Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer
Brief Summary: This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.


Options:
A: Arm Label: Arm I (anastrozole, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: gefitinib, Other: laboratory biomarker analysis | Arm Label: Arm II (fulvestrant, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: gefitinib, Drug: fulvestrant, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I (anastrozole, gefitinib) | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib) | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II (fulvestrant, gefitinib) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib)
B: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: fulvestrant | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anastrozole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fulvestrant, Drug: Anastrozole | Intervention Type: DRUG; Name: Fulvestrant; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Anastrozole; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fulvestrant, Drug: anastrozole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: fulvestrant | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: exemestane | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Control Trial of Commercial Weight Loss Programme in a Community Based Sample of Obese Adults.
Brief Summary: The objective is to compare the effectiveness of 4 different commercial weight-loss diets available to adults in the UK.

This is achieved with a 6 month multi-centre randomised unblinded controlled trial of

* Dr Atkins' New Diet Revolution,
* The slimFast Plan,
* The weight Watchers Pure Points Programme,
* Rosemary Conley's "Eat Yourself Slim" Diet \& Fitness Plan.
* No diet (control)

Subjects are a community based sample of 300 (60 per group) otherwise healthy overweight and obese adults.

Main outcome measures are weight and body fat change over 6 months.


Options:
A: Arm Label: energy-restricted, CHO-restricted diet; Type: EXPERIMENTAL; Interventions: Other: energy-restricted, CHO-restricted diet | Arm Label: energy-restricted, CHO-rich diet; Type: ACTIVE_COMPARATOR; Interventions: Other: energy-restricted, CHO-rich diet | Intervention Type: OTHER; Name: energy-restricted, CHO-restricted diet; Assigned to Arm(s): energy-restricted, CHO-restricted diet | Intervention Type: OTHER; Name: energy-restricted, CHO-rich diet; Assigned to Arm(s): energy-restricted, CHO-rich diet
B: Intervention Type: BEHAVIORAL; Name: calorie controlled diet; Assigned to Arm(s): N/A
C: Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Choice | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Choice; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial
Brief Summary: The purpose of this study is to compare the outcome in a broad perspective after laparoscopic Roux-en-Y gastric bypass and laparoscopic BPD-duodenal switch in the treatment of superobesity (body mass index \[BMI\] \> 50 kg/m2).


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: sleeve gastrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-Y-gastric bypass | Intervention Type: PROCEDURE; Name: sleeve gastrectomy; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Roux-Y-gastric bypass; Assigned to Arm(s): B
B: Arm Label: GBP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bariatric surgery: Gastric bypass | Arm Label: BPD 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bariatric surgery: Bilio-pancreatic diversion | Arm Label: Med Ter3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: anti-diabetic drugs and behavioral suggestions | Intervention Type: PROCEDURE; Name: Bariatric surgery: Gastric bypass; Assigned to Arm(s): GBP | Intervention Type: PROCEDURE; Name: Bariatric surgery: Bilio-pancreatic diversion; Assigned to Arm(s): BPD 2 | Intervention Type: BEHAVIORAL; Name: anti-diabetic drugs and behavioral suggestions; Assigned to Arm(s): Med Ter3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic operation Sleeve Gastrectomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic operation Roux-en-Y Gastric bypass | Intervention Type: PROCEDURE; Name: laparoscopic operation Sleeve Gastrectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: laparoscopic operation Roux-en-Y Gastric bypass; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic Biliopancreatic diversion with Duodenal switch | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Roux-en-Y Gastric Bypass | Intervention Type: PROCEDURE; Name: Laparoscopic Biliopancreatic diversion with Duodenal switch; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Laparoscopic Roux-en-Y Gastric Bypass; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA
Brief Summary: Background:

Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease. Moreover, MRI is not part of any of the established criteria and the precise role of MRI in early axial disease has not been fully defined yet. Even less is known about sacroiliac (SI) changes in SpA patients with peripheral symptoms. A pilot study using data from 'paper patients' led to new candidate criteria for early spondyloarthritis. Subsequently, the members of the ASAS International Working Group decided to conduct a prospective multi-centre study to evaluate (validate) the new candidate criteria, and to assess their performance as diagnostic criteria.

Aims of the study:

1. To evaluate the new candidate criteria for axial SpA in a multi-centre setting.
2. To assess the potential role of the new candidate criteria to be used as diagnostic criteria. To accomplish this, inclusion of consecutive and undiagnosed patients is mandatory as are longer periods of follow-up .
3. To compare criteria encompassing the whole group of SpA such as ESSG and Amor criteria against criteria which are tailored to either predominant axial disease or predominant peripheral disease. To accomplish this, both patients with predominant axial disease (back pain) but also patient with predominant peripheral disease (arthritis/enthesitis) will be included.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac + Omeprazole | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Diclofenac + Omeprazole; Assigned to Arm(s): B
B: Arm Label: All subjects; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): All subjects
C: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab (D2E7) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab (D2E7); Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA
Brief Summary: Background:

Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease. Moreover, MRI is not part of any of the established criteria and the precise role of MRI in early axial disease has not been fully defined yet. Even less is known about sacroiliac (SI) changes in SpA patients with peripheral symptoms. A pilot study using data from 'paper patients' led to new candidate criteria for early spondyloarthritis. Subsequently, the members of the ASAS International Working Group decided to conduct a prospective multi-centre study to evaluate (validate) the new candidate criteria, and to assess their performance as diagnostic criteria.

Aims of the study:

1. To evaluate the new candidate criteria for axial SpA in a multi-centre setting.
2. To assess the potential role of the new candidate criteria to be used as diagnostic criteria. To accomplish this, inclusion of consecutive and undiagnosed patients is mandatory as are longer periods of follow-up .
3. To compare criteria encompassing the whole group of SpA such as ESSG and Amor criteria against criteria which are tailored to either predominant axial disease or predominant peripheral disease. To accomplish this, both patients with predominant axial disease (back pain) but also patient with predominant peripheral disease (arthritis/enthesitis) will be included.


Options:
A: Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulphasalazine (SSZ) | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: sulphasalazine (SSZ); Assigned to Arm(s): B
D: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies of Early Diabetic Glomerulopathy-the Relation Between Histopathology, Kidney Function and Metabolic Control. Natural History and Effect of ARB
Brief Summary: The type 1 diabetes patients who were still normoalbuminuric and normotensive, after 17 years duration and a second research kidney biopsy, could enter the double blind treatment study of Atacand or Placebo.

The treatment study continues for five years treatment and ends with a third kidney biopsy.

The study hypothesis is that the effect of ARB during 5 years on the histopathology are more pronounced than the effect on histopathology of placebo.


Options:
A: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
Brief Summary: The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: pimozide; Type: EXPERIMENTAL; Interventions: Drug: Pimozide | Intervention Type: DRUG; Name: Pimozide; Assigned to Arm(s): pimozide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
C: Arm Label: Quetiapine or Risperidone + Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine or Risperidone + Aripiprazole | Arm Label: Quetiapine or Risperidone + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Quetiapine or Risperidone + placebo | Intervention Type: DRUG; Name: Quetiapine or Risperidone + Aripiprazole; Assigned to Arm(s): Quetiapine or Risperidone + Aripiprazole | Intervention Type: DRUG; Name: Quetiapine or Risperidone + placebo; Assigned to Arm(s): Quetiapine or Risperidone + placebo
D: Arm Label: Lurasidone Open-Label Arm A; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm C; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Intervention Type: DRUG; Name: Lurasidone HCl; Assigned to Arm(s): Lurasidone Open-Label Arm A, Lurasidone Open-Label Arm B, Lurasidone Open-Label Arm C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
Brief Summary: The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.


Options:
A: Arm Label: Risperidone, Intensive; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: risperidone, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: olanzapine, intensive; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: olanzapine, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: aripiprazole, intensive; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: aripiprazole, basiv; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone, Intensive, risperidone, basic | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): olanzapine, basic, olanzapine, intensive | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): aripiprazole, basiv, aripiprazole, intensive
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
Brief Summary: The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Intervention Type: DRUG; Name: Seroquel (quetiapine); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Premier Lifestyle Intervention with DASH Diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Premier Lifestyle Intervention with DASH Diet; Assigned to Arm(s): 1
D: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Secondary Prevention After Ischemic Stroke: A Trial of an Evidence-Based System-Wide Intervention
Brief Summary: Is a secondary prevention intervention, focused on implementation of standardized pre-printed discharge orders for hospitalists, effective at increasing utilization of the following evidence-based treatments 6 months after discharge for ischemic stroke:

1. Treatment with statins,
2. Control of hypertension, and
3. Anticoagulation in patients with atrial fibrillation.


Options:
A: Intervention Type: DRUG; Name: Optimal treatment; Assigned to Arm(s): N/A
B: Arm Label: 1: Care management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: 2: Written Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Materials | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): 1: Care management | Intervention Type: BEHAVIORAL; Name: Written Materials; Assigned to Arm(s): 2: Written Materials
C: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Instruction in physical training program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Instruction in physical training program; Assigned to Arm(s): Intervention arm
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention - a validated home BP monitor and support from the specialist nurse | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control - usual care (BP monitoring by their practice) | Intervention Type: BEHAVIORAL; Name: Intervention - a validated home BP monitor and support from the specialist nurse; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Control - usual care (BP monitoring by their practice); Assigned to Arm(s): Control

Answer: A